ECSP22078815A - Anticuerpos anti-phf-tau y usos de estos - Google Patents

Anticuerpos anti-phf-tau y usos de estos

Info

Publication number
ECSP22078815A
ECSP22078815A ECSENADI202278815A ECDI202278815A ECSP22078815A EC SP22078815 A ECSP22078815 A EC SP22078815A EC SENADI202278815 A ECSENADI202278815 A EC SENADI202278815A EC DI202278815 A ECDI202278815 A EC DI202278815A EC SP22078815 A ECSP22078815 A EC SP22078815A
Authority
EC
Ecuador
Prior art keywords
antibodies
phf
tau antibodies
tau
tauopathies
Prior art date
Application number
ECSENADI202278815A
Other languages
English (en)
Inventor
Kolen Kristof Van
Porte Sherry La
Marc Mercken
Jinquan Luo
Sanjaya Singh
Sathyadevi Venkataramani
Rupesh Nanjunda
Pharavee Jaiprasart
Rajkumar Ganesan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of ECSP22078815A publication Critical patent/ECSP22078815A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Se describen anticuerpos monoclonales anti-PHF-tau y fragmentos de unión al antígeno de estos. Además, se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y usar los anticuerpos para tratar o prevenir afecciones, tales como tauopatías.
ECSENADI202278815A 2020-04-08 2022-10-07 Anticuerpos anti-phf-tau y usos de estos ECSP22078815A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063007118P 2020-04-08 2020-04-08
US202063026387P 2020-05-18 2020-05-18

Publications (1)

Publication Number Publication Date
ECSP22078815A true ECSP22078815A (es) 2022-11-30

Family

ID=78023121

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202278815A ECSP22078815A (es) 2020-04-08 2022-10-07 Anticuerpos anti-phf-tau y usos de estos

Country Status (20)

Country Link
US (1) US20230151083A1 (es)
EP (1) EP4132569A4 (es)
JP (1) JP2023521763A (es)
KR (1) KR20220166308A (es)
CN (1) CN115697393A (es)
AU (1) AU2021251486A1 (es)
BR (1) BR112022020410A2 (es)
CA (1) CA3179914A1 (es)
CL (1) CL2022002766A1 (es)
CO (1) CO2022015737A2 (es)
CR (1) CR20220505A (es)
DO (1) DOP2022000218A (es)
EC (1) ECSP22078815A (es)
IL (1) IL297231A (es)
JO (1) JOP20220255A1 (es)
MX (1) MX2022012628A (es)
PE (1) PE20230385A1 (es)
PH (1) PH12022553035A1 (es)
TW (1) TW202204402A (es)
WO (1) WO2021205359A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092088A1 (ru) 2018-03-05 2020-11-13 Янссен Фармацевтика Нв Антитела анти-phf-тау и их применение
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
TW202346355A (zh) * 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(二)
AU2023232448A1 (en) * 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2794654T (pt) * 2011-12-20 2019-09-10 Janssen Biotech Inc Anticorpos anti-phf-tau e suas utilizações
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
MX2017015908A (es) * 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
TWI771389B (zh) * 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
MA53338A (fr) * 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
CN115698074A (zh) * 2020-04-08 2023-02-03 阿里亚达治疗公司 抗-cd98抗体和其用途
EP4132589A4 (en) * 2020-04-08 2024-05-08 Aliada Therapeutics, Inc. COMPOSITIONS AND METHODS OF ADMINISTRATION AT THE BLOOD-BRAIN BARRIER

Also Published As

Publication number Publication date
CO2022015737A2 (es) 2023-02-27
CL2022002766A1 (es) 2023-04-21
TW202204402A (zh) 2022-02-01
US20230151083A1 (en) 2023-05-18
MX2022012628A (es) 2023-01-11
AU2021251486A1 (en) 2022-12-08
PH12022553035A1 (en) 2024-05-13
EP4132569A1 (en) 2023-02-15
JOP20220255A1 (ar) 2022-10-06
CA3179914A1 (en) 2021-10-14
KR20220166308A (ko) 2022-12-16
PE20230385A1 (es) 2023-03-06
BR112022020410A2 (pt) 2023-01-03
DOP2022000218A (es) 2023-04-30
IL297231A (en) 2022-12-01
WO2021205359A1 (en) 2021-10-14
CR20220505A (es) 2023-05-31
EP4132569A4 (en) 2024-07-31
JP2023521763A (ja) 2023-05-25
CN115697393A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
DOP2022000218A (es) Anticuerpos anti-phf-tau y usos de estos
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
DOP2021000229A (es) Materiales y métodos para modular la inmunidad mediada por cédula t
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2020001309A (es) Anticuerpos anti-cd47 y sus usos.
UY39699A (es) Anticuerpos anti-tau y usos de estos
UY39698A (es) Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos
CO2024012037A2 (es) Anticuerpos multiespecíficos y usos de estos
AR053608A1 (es) Anticuerpos anti-gm-csf y usos de los mismos
MX2018013548A (es) Proteinas de union biespecificas y usos de las mismas.
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
BR112023020450A2 (pt) Anticorpos anti-cd19 e estruturas car-t
PH12020551373A1 (en) Anti-phf-tau antibodies and uses thereof
EA202190807A1 (ru) Антитела к синуклеину
MX2020006105A (es) Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
ECSP19008417A (es) Anticuerpos con inmunogenicidad baja y usos de estos
EA202092122A1 (ru) Антитела против tip-1 и их применения
DOP2025000164A (es) Anticuerpos anti-unc5c
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
AR130536A1 (es) Anticuerpos que se unen a cd228
EA202092840A1 (ru) Антитела к cd33, биспецифические антитела к cd33/cd3 и их применение
AR115424A1 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33 / anti-cd3 y usos de estos